Angelini Pays $4.1B for Catalyst's Rare Neuro Drugs
Angelini Pharma dropped $4.1B on Catalyst and its trio of FDA-approved rare neurology treatments; the per-share premium wasn't disclosed.
Angelini Pharma dropped $4.1B on Catalyst and its trio of FDA-approved rare neurology treatments; the per-share premium wasn't disclosed.
GSK paid up to $1B for SiranBio's Phase 1 siRNA asset targeting ALK7, doubling down on cardiometabolic bets while GLP-1 rivals pile up.
Four Chime customers allege Iran-linked Team 313 stole Social Security numbers and account credentials; Chime says no member data was compromised.
Elegrobart's REVEAL-2 hit 54% PRR, vindicating Viridian after REVEAL-1 crashed shares 33% — and Q1 2027 filing is now on the table.
Lilly's $4.5B Lebanon push brings its U.S. decade commitment over $50B, with a tirzepatide API plant poised to be the country's largest.
The crypto exchange is paying $4.2B for capital markets plumbing: a transfer agent processing $500B annually for 20 million shareholders.
A Latvian national drew 102 months for his role in a Conti offshoot's $16M ransomware spree, including leaking children's health data.
Maryland's AI pricing ban starts with grocers and delivery apps. The language used fits every risk-based pricing model in consumer finance.
A Character.AI chatbot posed as a licensed psychiatrist in 45,500 sessions. Pennsylvania's lawsuit says it even gave out a fake license number.
The Conti operator who threatened to leak stolen children's health records to extort payment just drew 102 months from DOJ's Criminal Division.
Madrigal's $1B bet on Arrowhead's ARO-PNPLA3 targets a PNPLA3 mutation affecting 30% of MASH patients that Rezdiffra doesn't cover.
Edge's autofill keeps plaintext passwords in process memory, creating a dump-and-steal path that sidesteps both Windows Hello and DPAPI.
A USB drop test went viral in 2026 because employees plugged in the drives within hours, exposing a gap in phishing-focused security programs.
A blood test that predicts who responds to Wegovy could hand payers the tool they need to narrow GLP-1 coverage, and Viridian cleared Phase 3 again.
Two chained CVEs in Ollama's Windows updater drop persistent RCE payloads on login, and three months after disclosure, there's still no patch.